Maxim Group initiated coverage on Zivo Bioscience with a new price target
$ZIVO
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2021 | $9.00 | Buy | Maxim Group |
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
SCHEDULE 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025 Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens. Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions with a number of major global animal health companies regarding a potential exclusive lice
Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI wh
ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO's non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds
Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)